Tue Dec 24 18:40:19 UTC 2024: **Senores Pharmaceuticals IPO Oversubscribed, Grey Market Premium Soars**

**Mumbai, India – December 24, 2024** – The initial public offering (IPO) of Senores Pharmaceuticals Limited, which closed today at 5:00 PM, has been significantly oversubscribed. The book-building issue received a strong response from investors, driving up the grey market premium (GMP).

By the end of the bidding period, the IPO was oversubscribed 78.78 times overall. The retail portion saw 81.01 times oversubscription, while the Non-Institutional Investor (NII) and Qualified Institutional Buyer (QIB) segments were subscribed 91.44 and 72.62 times respectively.

The grey market premium, an unofficial indicator of investor sentiment, surged to ₹233, a ₹33 increase from Monday’s ₹200. Market observers attribute this surge to the strong investor response and a recent positive trend reversal on the Dalal Street stock exchange. The current GMP suggests a 60% premium over the upper price band of ₹391 per share.

Several prominent brokerage firms, including Motilal Oswal and Anand Rathi, have recommended subscribing to the IPO. Motilal Oswal highlighted Senores’ strong niche in the pharmaceutical industry and its fair valuation, while Anand Rathi emphasized the company’s global presence and strong financials. Aditya Birla, BP Equities, Canara Bank Securities, Eureka Stock & Share Broking Services, SBI Capital Securities, and Ventura Securities also issued “subscribe” ratings.

Senores Pharmaceuticals develops and manufactures pharmaceutical products for regulated markets in the US, Canada, and the UK, as well as emerging markets. The company operates in 43 countries, focusing on critical care injectables, APIs, and complex specialty pharmaceutical products.

*Disclaimer: This news article summarizes information from various sources. Investors are advised to conduct their own thorough research and consult with financial advisors before making any investment decisions.*

Read More